Partner Fund Management LP Maintains Stake in Aerie Pharmaceuticals INC (AERI)

March 14, 2018 - By Adrian Erickson

Investors sentiment increased to 1.73 in 2017 Q3. Its up 0.56, from 1.17 in 2017Q2. It is positive, as 14 investors sold AERI shares while 41 reduced holdings. 26 funds opened positions while 69 raised stakes. 34.42 million shares or 8.89% more from 31.61 million shares in 2017Q2 were reported. Essex Management Comm Ltd has 80,366 shares. Jennison Ltd Co has 0.09% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 1.88M shares. Palisade Cap Ltd Nj reported 0.01% stake. Voya Investment Management Limited Liability Corporation holds 0.05% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 501,741 shares. Stifel Fincl Corporation has invested 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Moreover, Metropolitan Life Ins has 0.01% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Credit Suisse Ag has invested 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). New York-based Sg Americas Ltd Liability Corp has invested 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Maryland-based Proshare Advsr Ltd Liability has invested 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Broadfin Cap Limited Liability Corp reported 64,800 shares. First Personal Fincl holds 535 shares or 0.01% of its portfolio. Jgp Gestao De Recursos Ltda invested in 13,844 shares or 0.69% of the stock. Deerfield Co reported 632,686 shares. The New York-based Senzar Asset Mgmt Limited Liability Co has invested 2.74% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Leisure Cap Mngmt reported 16,906 shares.

Christopher Medlock James increased its stake in Aerie Pharmaceuticals Inc (AERI) by 38.07% based on its latest 2017Q3 regulatory filing with the SEC. Partner Fund Management Lp bought 665,421 shares as the company’s stock declined 8.47% while stock markets rallied. The hedge fund run by Christopher Medlock James held 2.41 million shares of the health care company at the end of 2017Q3, valued at $117.29 million, up from 1.75 million at the end of the previous reported quarter. Partner Fund Management Lp who had been investing in Aerie Pharmaceuticals Inc for a number of months, seems to be bullish on the $2.29 billion market cap company. The stock decreased 0.09% or $0.05 during the last trading session, reaching $57.9. About 236,630 shares traded. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has risen 180.20% since March 14, 2017 and is uptrending. It has outperformed by 163.50% the S&P500.

Partner Fund Management Lp, which manages about $5.09 billion US Long portfolio, decreased its stake in Clovis Oncology Inc (Prn) by 12.08 million shares to 34.71 million shares, valued at $53.67M in 2017Q3, according to the filing. It also reduced its holding in Facebook Inc (Call) (NASDAQ:FB) by 81,499 shares in the quarter, leaving it with 224,700 shares, and cut its stake in Kite Pharma Inc (NASDAQ:KITE).

More notable recent Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news were published by: which released: “Why Earnings Season Could Be Great for Aerie Pharmaceuticals (AERI)” on February 27, 2018, also with their article: “Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial …” published on February 28, 2018, published: “Aerie Pharmaceuticals Announces Appointment of John LaRocca as General Counsel” on February 20, 2018. More interesting news about Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) were released by: and their article: “Aerie Pharmaceuticals to Present at the Cowen and Company 38” published on February 21, 2018 as well as‘s news article titled: “Aerie Pharmaceuticals to Present at the Oppenheimer & Co. 28” with publication date: February 28, 2018.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

Among 15 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 15 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals had 49 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, July 20. The stock has “Buy” rating by H.C. Wainwright on Tuesday, September 20. The stock has “Buy” rating by Aegis Capital on Tuesday, November 1. The firm earned “Buy” rating on Thursday, September 15 by Cantor Fitzgerald. Canaccord Genuity maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating on Tuesday, August 1. Canaccord Genuity has “Buy” rating and $6500 target. Canaccord Genuity maintained the stock with “Buy” rating in Monday, October 16 report. The firm has “Buy” rating given on Friday, September 22 by JMP Securities. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Cowen & Co on Wednesday, August 2. The rating was reinitiated by H.C. Wainwright on Friday, February 16 with “Buy”. On Thursday, September 15 the stock rating was maintained by Stifel Nicolaus with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.